[vc_row padding_top=”0px” padding_bottom=”0px”][vc_column fade_animation_offset=”45px” width=”1/2″][image type=”thumbnail” src=”1297″ alt=”” href=”” title=”” info_content=”” lightbox_caption=”” id=”” class=”” style=””][/vc_column][vc_column fade_animation_offset=”45px” width=”1/2″][text_output]Horizon 2020 Consortium meeting was held on Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters in Copenhagen, Denmark July 4-6 2017 .
The meeting of the Steering Committee has included the review of the project progress, milestones and planning of actions for the next six months together with the second TAT-CF Workshop.
Our screening development leader Dr. László Hackler presented the results of end-point toxicity assays on Avidin’s newly synthetized 19 compounds in this last period. Lead compounds were further tested with Real time cell-electronic sensing and Holographic microscopy.
Seminar title: Cellular screening technologies regarding to toxicity and side effects.
https://tat-cf.eu/meeting-in-copenhagen/[/text_output][/vc_column][/vc_row]